Drugs / ALVAC-CEA-B7.1
last change Aug 2008 re-read 2 minutes ago

ALVAC-CEA-B7.1

Developed for
colorectal cancer
Investigated by
Herbert Irving Comprehensive Cancer Center · National Cancer Institute (NCI)

Trials 1 · a red edge is where a trial was stopped

20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00027833 Dec 2001 → ? colorectal cancer Herbert Irving Comprehensive Cancer Center Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as ALVAC-CEA/B7.1 “Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer.” PMID 18676757 Aug 2008
1

NCT00027833

Route Subcutaneous “ALVAC-CEA-B7.1 vaccine subcutaneously (SC) once weekly for 3 weeks” NCT00027833